Literature DB >> 10090646

Abstinence symptoms following oral THC administration to humans.

M Haney1, A S Ward, S D Comer, R W Foltin, M W Fischman.   

Abstract

Symptoms of dependence and withdrawal after the frequent administration of high doses (210 mg/day) of oral delta9-tetrahydrocannabinol (THC) have been reported, yet little is known about dependence on lower oral THC doses, more relevant to levels attained by smoking marijuana. In a 20-day residential study, male (n = 6) and female (n = 6) marijuana smokers worked on five psychomotor tasks during the day (0915-1700 hours), and in the evening engaged in private or social recreational activities (1700-2330 hours); subjective-effects measures were completed 10 times/day, and a sleep questionnaire was completed each morning. Food and beverages were available ad libitum from 0830 to 2330 hours. Capsules were administered at 1000, 1400, 1800, and 2200 hours. Placebo THC was administered on days 1-3, 8-11, and 16-19. Active THC was administered on days 4-7 (20 mg qid) and on days 12-15 (30 mg qid). Both active doses of THC increased ratings of "High," "Good Drug Effect," and "Willingness to Take Dose Again" compared to baseline (days 1-3). THC also increased food intake by 35-45%, and decreased verbal interaction among participants compared to placebo baseline. Tolerance developed to the subjective effects of THC but not to its effects on food intake or social behavior. Abstinence from THC increased ratings of "Anxious," "Depressed," and "Irritable," decreased the reported quantity and quality of sleep, and decreased food intake by 20-30% compared to baseline. These behavioral changes indicate that dependence develops following exposure to lower daily doses of THC than have been previously studied, suggesting that the alleviation of abstinence symptoms may contribute to the maintenance of daily marijuana use.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10090646     DOI: 10.1007/s002130050848

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  75 in total

1.  Cannabinoids and metabolites in expectorated oral fluid after 8 days of controlled around-the-clock oral THC administration.

Authors:  Garry Milman; Allan J Barnes; David M Schwope; Eugene W Schwilke; Robert S Goodwin; Deana L Kelly; David A Gorelick; Marilyn A Huestis
Journal:  Anal Bioanal Chem       Date:  2011-06-03       Impact factor: 4.142

2.  Disposition of cannabinoids in oral fluid after controlled around-the-clock oral THC administration.

Authors:  Garry Milman; Allan J Barnes; David M Schwope; Eugene W Schwilke; William D Darwin; Robert S Goodwin; Deanna L Kelly; David A Gorelick; Marilyn A Huestis
Journal:  Clin Chem       Date:  2010-06-08       Impact factor: 8.327

Review 3.  Animal models of cannabinoid reward.

Authors:  Leigh V Panlilio; Zuzana Justinova; Steven R Goldberg
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

4.  Effects of chronic marijuana use on brain activity during monetary decision-making.

Authors:  Jatin G Vaidya; Robert I Block; Daniel S O'Leary; Laura B Ponto; Mohamed M Ghoneim; Antoine Bechara
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

Review 5.  The marijuana withdrawal syndrome: diagnosis and treatment.

Authors:  Margaret Haney
Journal:  Curr Psychiatry Rep       Date:  2005-10       Impact factor: 5.285

6.  Dose-related differences in the regional pattern of cannabinoid receptor adaptation and in vivo tolerance development to delta9-tetrahydrocannabinol.

Authors:  Diana L McKinney; Michael P Cassidy; Lauren M Collier; Billy R Martin; Jenny L Wiley; Dana E Selley; Laura J Sim-Selley
Journal:  J Pharmacol Exp Ther       Date:  2007-10-29       Impact factor: 4.030

Review 7.  Marijuana dependence: not just smoke and mirrors.

Authors:  Divya Ramesh; Joel E Schlosburg; Jason M Wiebelhaus; Aron H Lichtman
Journal:  ILAR J       Date:  2011

8.  Marijuana withdrawal and aggression among a representative sample of U.S. marijuana users.

Authors:  Philip H Smith; Gregory G Homish; Kenneth E Leonard; R Lorraine Collins
Journal:  Drug Alcohol Depend       Date:  2013-02-04       Impact factor: 4.492

Review 9.  Role of endocannabinoid system in mental diseases.

Authors:  Jorge Manzanares; Leyre Urigüen; Gabriel Rubio; Tomás Palomo
Journal:  Neurotox Res       Date:  2004       Impact factor: 3.911

10.  Delta9-tetrahydrocannabinol (THC), 11-hydroxy-THC, and 11-nor-9-carboxy-THC plasma pharmacokinetics during and after continuous high-dose oral THC.

Authors:  Eugene W Schwilke; David M Schwope; Erin L Karschner; Ross H Lowe; William D Darwin; Deanna L Kelly; Robert S Goodwin; David A Gorelick; Marilyn A Huestis
Journal:  Clin Chem       Date:  2009-10-15       Impact factor: 8.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.